China’s National Healthcare Security Administration (NHSA), the government agency that oversees health insurance schemes and organizes annual negotiations of drug prices, released on 28 November the updated 2024 National Reimbursement Drug List (NRDL), marking the seventh time this has been updated since the agency was established in 2018.
Enhertu Among Drugs In Annual China NRDL Update
Local Companies Dominate But No CAR-Ts
The majority of new drugs added to the latest revision of China's NRDL were developed by Chinese companies, although half of the global top 20 pharmas also have new entries. Bispecifics were included for the first time but no CAR-Ts made the cut.
